Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
about
The biology and treatment of EML4-ALK non-small cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer: results and open issuesMucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar featuresDifferences in driver genes between smoking-related and non-smoking-related lung cancer in the Chinese populationMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularGood clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).Proteomic approach to biomarker discovery in cancer tissue from lung adenocarcinoma among nonsmoking Chinese women in Hong Kong.Promoter methylation of RASSF1A and DAPK and mutations of K-ras, p53, and EGFR in lung tumors from smokers and never-smokers.Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancerGenetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissueMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularMolecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CTFrequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer.Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Epidermal growth factor receptor inhibition and non-small cell lung cancer.Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancersComparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial CancerThe ERBB3 receptor in cancer and cancer gene therapyEGFR and KRAS mutations in patients with adenocarcinoma of the lung.Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.Epidermal growth factor receptor mutation in adenocarcinoma lung in a North Indian population: Prevalence and relation with different clinical variables.Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.The impact of smoking status on radiologic tumor progression patterns and response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer.Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?KRAS mutation detection in paired frozen and Formalin-Fixed Paraffin-Embedded (FFPE) colorectal cancer tissuesDetection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.Epidermal growth factor receptor mutations and their correlation with epidermal growth factor receptor-tyrosine kinase inhibitor therapy and association with the characteristics of patients with non-small-cell lung cancer: A meta-analysis.Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer.Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor receptor somatic mutation in patients with advanced non-squamous, non-small cell lung cancer.Theoretical method for evaluation of therapeutic effects and adverse effects of epidermal growth factor receptor tyrosine kinase inhibitors in clinical treatment.PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients.
P2860
Q24632625-9E09539E-27F9-4C9F-B1BA-70329B287147Q24653036-3DA88B30-0D0B-4C30-890A-FDBECE058E1DQ24683814-B786741D-27F4-46F6-B68E-CB0CA213AE2EQ26786594-46F763A1-17B8-4762-85A4-9F1B9F770B2EQ26828860-699E0841-7216-432E-98C7-20289DD39C5DQ27851566-69BF2A29-0BDE-4F71-AF60-025CC8FF7EDEQ30840907-1AC3AB79-A170-461F-8830-94EC9D0AB392Q33283634-D7C30286-CB39-4BC4-ACDC-ABFB9DD44503Q33798819-329C2664-F4CE-4A1A-8602-96A0FEAE7522Q33807653-91982143-CB34-4B5F-8FA2-A86C4165518CQ33856261-48C92335-993A-4B81-8644-C350C917981DQ34159011-A3C7BEBE-4084-49C3-924F-6AB9E6F8880DQ34534164-26E78EB3-2212-4C1D-9176-5A3FF525EE9DQ35016912-04E6822D-68BC-40A4-B1C3-0C7A35EFDC30Q35232230-287AFAEF-C370-4AD2-B7C5-9FF08D58870BQ35956330-FC680AB1-5367-4FF5-8E2D-7EF6371E3D8FQ36250691-A112AA54-11D9-41DA-B2A4-6B9EA3350BE3Q36504349-37DDE159-6AE2-4A04-A2AD-2EF8A99431A5Q36905639-600A6A29-CDD4-42C8-B898-ECE9F60E04FFQ36951322-EE3DFD3E-EEDA-4385-B874-53671A37FE39Q37135372-DEB17FD8-7286-4564-A4A3-630091411CF5Q37205334-1D63073C-860A-48D1-9372-78D872DBA002Q37252270-BB407707-66D7-49A4-93F5-22FA4ADEA530Q37265114-4C7620A4-7407-40FF-BD2E-EE243DB9F146Q37334996-6E00CDF0-E83F-46DC-8055-E9CF6E41AFC5Q37528193-3B251183-75B9-4606-920F-819B3AC86791Q37579644-BD7AD995-CA1E-4915-8DF3-7611CA41DC64Q37755154-BC556082-AFD9-4520-BA32-787A649BB63DQ38023942-27E423E0-6477-474F-9B6E-3F1ECE510E44Q38096472-E59C8A8D-D602-4043-8436-558B07B746C5Q38409695-FB00451C-1529-4AD8-A946-7BE2DC5F8524Q39437297-4BE8CF4B-4DCC-48FE-A19C-2EAB9D87431CQ40041019-BE14F3F8-571C-4714-A91C-1A03074A95DEQ42288481-728F7559-A750-4143-BAF3-B62AA66337ACQ42745155-B17D165E-C9F9-411E-88A9-053BD158509CQ45965455-6601B183-54EC-4A4D-BCB1-BF0392458B85Q46351405-D283923B-B04C-41C8-9484-ED92F3D706F5Q48100116-2958041F-4B64-480D-A87C-D4BF5948C6D9Q50053003-DAD40CCF-A996-4EBA-AAF3-55B519FC5A5CQ54179471-6E38FEA6-24E2-4A7C-AEC5-EF7F8CBE00BF
P2860
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Clinicopathologic significance ...... th non-small cell lung cancer.
@en
Clinicopathologic significance ...... th non-small cell lung cancer.
@nl
type
label
Clinicopathologic significance ...... th non-small cell lung cancer.
@en
Clinicopathologic significance ...... th non-small cell lung cancer.
@nl
prefLabel
Clinicopathologic significance ...... th non-small cell lung cancer.
@en
Clinicopathologic significance ...... th non-small cell lung cancer.
@nl
P2093
P1476
Clinicopathologic significance ...... th non-small cell lung cancer.
@en
P2093
Atsushi Takise
Hironobu Iijima
John D Minna
Kunio Dobashi
Masatomo Mori
Noriaki Sunaga
Ryusei Saito
Shigefumi Tanaka
Takashi Nakajima
P304
P356
10.1158/1078-0432.CCR-05-0441
P407
P433
P577
2005-10-01T00:00:00Z